Clinical Trials Browser

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body

Biochemically Recurrent Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma of the Prostate

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Metastatic Hormone Sensitive Prostate Cancer

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body

Breast Neoplasms

Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Breast Neoplasms

Recurrent Endometrial Endometrioid Adenocarcinoma

Breast Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Neoplasm Metastasis, Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

Intermediate Risk Prostate Cancer

Advanced Epithelial Ovarian

Metastatic Castration-resistant Prostate Cancer

Clinical Trials

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

TRAP

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

KEYNOTE-991

ARAMON

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

PROSPER

CheckMate 9KD

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

ARCHES

ARROW

KEYNOTE-991

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

TRITON3

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

KEYLYNK-010

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

PRESIDE

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

UPWARD

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

ENACT

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

IMbassador250

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

PLATO

RAMP

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Enzalutamide + External Beam Rt For Prostate

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer